nSMOL – Combining Nano Technology with LC-MS for Improved mAb Analysis
1 May 2018
Determining the efficacy and toxicity of biotherapeutics, such as mAbs, is fundamental to the development process. Whilst ELISA is a long-standing process used to determine drug concentration in blood samples, there are a number of caveats associated with its efficiancy and sensitivity that can be largely overcome with LCMS. To streamline the process further, Shimadzu have developed an innovative nanotechnology-based bioanalysis kit, nSMOLTM, to eliminate sample preparation processes and increase the detection sensitivity further.
About the company
Shimadzu Corporation
Shimadzu Corporation was founded in Kyoto, Japan in 1875 and has been supplying cutting-edge analytical and measuring instruments for a broad range of applications for over 140 years. Key markets include pharmaceuticals, life sciences, food & beverages, chemicals, petrochemicals, environmental, material science, and forensics/toxicology. Products include chromatographs (HPLC/UHPLC/SFC, GC), mass spectrometers (GC-MS/MS, LC-MS/MS, MALDI, ICP-MS), spectrophotometers (FT-IR, Fluorescence, UV-VIS-NIR), atomic spectrometers (AA, ICP), X-ray spectrometers (ED-XRF, XRD, XRF), thermal analyzers, Total Organic Carbon (TOC) analyzers, particle size analyzers, material testing machines, and balances, etc.
